Compass Therapeutics Stock

Compass Therapeutics P/B

The P/B (Price-to-Book Ratio) of Compass Therapeutics (CMPX) as of Aug 16, 2026 is 5.68. In the previous year, P/B (Price-to-Book Ratio) was 8.92 — a change of -36.36% (lower).

P/B

5.68

YoY

-36.36%

Last updated:

P/B (Price-to-Book Ratio) of Compass Therapeutics is 2026 5.68 . P/B (Price-to-Book Ratio) of Compass Therapeutics was 2025 8.92 . It decreases by -36.36% lower compared to the previous year.
Access this data via the Eulerpool API

Compass Therapeutics Stock analysis

What does Compass Therapeutics do? Compass Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Compass Therapeutics stock

P/B (Price-to-Book Ratio) of Compass Therapeutics is 5.68 in 2026.

P/B (Price-to-Book Ratio) of Compass Therapeutics changed from 8.92 to 5.68, representing a -36.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Compass Therapeutics since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Compass Therapeutics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Compass Therapeutics

All Key Metrics — Compass Therapeutics